Konakion Mm Ampoules

Phytomenadione, the active ingredient in Konakion Mm Ampoules, is a vitamin K presented as an injectable solution for intravenous or oral use. It is employed to correct vitamin K deficiency and to support normal clotting in patients at risk of bleeding, including newborns and individuals on anticoagulant therapy.

GNH USA supplies Konakion Mm Ampoules as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Konakion Mm provides vitamin K supplementation to address disorders of the coagulation cascade.

- Vitamin K deficiency: restores functional clotting factor activity in deficient patients. - Hemorrhagic disease of the newborn: prevents bleeding in neonates at risk. - Anticoagulation reversal: counteracts the effects of warfarin or other vitamin K antagonists. - Liver‑related coagulopathy: supports clot formation in patients with impaired hepatic synthesis of clotting factors.

Adverse reactions may occur following administration of Konakion Mm Ampoules.

Common Side Effects: - Injection site pain or erythema. - Transient flushing or warmth. - Mild hypotension. - Nausea or vomiting. - Headache.

Serious or Rare Side Effects: - Anaphylactic reaction, including urticaria and respiratory distress. - Thrombosis or embolic events. - Severe hemolysis (rare).

Use Konakion Mm with appropriate clinical monitoring and consideration of patient-specific factors.

- Hepatic impairment: assess coagulation status before administration. - Concurrent anticoagulants: monitor INR or PT closely. - Neonates: use age‑appropriate dosing and monitor for hyperbilirubinemia. - Pregnancy: safety not established; use only if benefit outweighs potential risk. - Known hypersensitivity: avoid administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Phytomenadione may interact with several medications affecting coagulation.

Major Interactions (Avoid): - Warfarin: may reduce anticoagulant effect, requiring dose adjustment. - Broad‑spectrum antibiotics (e.g., cephalosporins): can interfere with vitamin K synthesis and alter efficacy.

Moderate Interactions (Monitor Closely): - Heparin: additive anticoagulant effect may increase bleeding risk. - Oral contraceptives: potential increased risk of thrombosis. - Other vitamin K‑containing products: may modify therapeutic response.